Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...